These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 31156811)

  • 41. Stability of midazolam hydrochloride injection 1-mg/mL solutions in polyvinyl chloride and polyolefin bags.
    Karlage K; Earhart Z; Green-Boesen K; Myrdal PB
    Am J Health Syst Pharm; 2011 Aug; 68(16):1537-40. PubMed ID: 21817086
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Formulating a poorly water soluble drug into an oral solution suitable for paediatric patients; lorazepam as a model drug.
    van der Vossen AC; van der Velde I; Smeets OS; Postma DJ; Eckhardt M; Vermes A; Koch BC; Vulto AG; Hanff LM
    Eur J Pharm Sci; 2017 Mar; 100():205-210. PubMed ID: 28126558
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stability of propranolol hydrochloride suspension compounded from tablets.
    Henry DW; Repta AJ; Smith FM; White SJ
    Am J Hosp Pharm; 1986 Jun; 43(6):1492-5. PubMed ID: 3728486
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations.
    Sicouri S; Pourrier M; Gibson JK; Lynch JJ; Antzelevitch C
    Heart Rhythm; 2012 Mar; 9(3):422-9. PubMed ID: 22019863
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stability of an extemporaneously compounded levothyroxine sodium oral liquid.
    Boulton DW; Fawcett JP; Woods DJ
    Am J Health Syst Pharm; 1996 May; 53(10):1157-61. PubMed ID: 8734676
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Permeation studies through porcine small intestine of furosemide solutions for personalised paediatric administration.
    Provenza N; Calpena AC; Mallandrich M; Sánchez A; Egea MA; Clares B
    Int J Pharm; 2014 Nov; 475(1-2):208-13. PubMed ID: 25178830
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Stability of ursodiol in an extemporaneously compounded oral liquid.
    Johnson CE; Nesbitt J
    Am J Health Syst Pharm; 1995 Aug; 52(16):1798-1800. PubMed ID: 8528836
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Formulation and accelerated stability studies for an extemporaneous suspension of amiodarone hydrochloride.
    Alexander KS; Thyagarajapuram N
    Int J Pharm Compd; 2003; 7(5):389-93. PubMed ID: 23979771
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma.
    Teeranachaideekul V; Boonsongsawat W; Asanawittaya W; Jintapattanakit A; Chantasart D; Wongrakpanich A
    Int J Pharm Compd; 2021; 25(1):62-72. PubMed ID: 33503011
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Simplified Extemporaneously Prepared Potassium Chloride Oral Solution.
    Tannous E; Tal Y; Amarny K
    Int J Pharm Compd; 2016; 20(5):438-439. PubMed ID: 28339380
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia.
    Läer S; Elshoff JP; Meibohm B; Weil J; Mir TS; Zhang W; Hulpke-Wette M
    J Am Coll Cardiol; 2005 Oct; 46(7):1322-30. PubMed ID: 16198851
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term stability of extemporaneously prepared captopril oral liquids in glass bottles.
    Brustugun J; Lao YE; Fagernaes C; Braenden J; Kristensen S
    Am J Health Syst Pharm; 2009 Oct; 66(19):1722-5. PubMed ID: 19767378
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of pH, chlorobutanol, cysteine hydrochloride, ethylenediaminetetraacetic acid, propylene glycol, sodium metabisulfite, and sodium sulfite on furosemide stability in aqueous solutions.
    Shah KA; Das Gupta V; Stewart KR
    J Pharm Sci; 1980 May; 69(5):594-6. PubMed ID: 6770073
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products.
    Glass BD; Haywood A
    J Pharm Pharm Sci; 2006; 9(3):398-426. PubMed ID: 17207422
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Formulation and stability study of an oral paediatric phenobarbital 1% solution containing hydroxypropyl-β-cyclodextrins.
    Parrenne L; Ribier Z; Abisror J; Cadix J; Benoit G; Bordenave J
    Eur J Hosp Pharm; 2024 Jun; 31(4):363-368. PubMed ID: 36754621
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of an extemporaneous oral liquid formulation of oxandrolone and its stability evaluation.
    Garg A; Garg S; She RW
    Burns; 2011 Nov; 37(7):1150-3. PubMed ID: 21764219
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative Stability Study of Unit-dose Vancomycin Hydrochloride Oral Solutions in Plastic Capped Oral Syringes and Plastic Sealed Dosage Cups.
    Brown S; Lewis P
    Int J Pharm Compd; 2020; 24(3):234-237. PubMed ID: 32401742
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Stability of a flavored formulation of acetylcysteine for oral administration.
    Siden R; Johnson CE
    Am J Health Syst Pharm; 2008 Mar; 65(6):558-61. PubMed ID: 18319502
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Stability of tacrolimus in an extemporaneously compounded oral liquid.
    Jacobson PA; Johnson CE; West NJ; Foster JA
    Am J Health Syst Pharm; 1997 Jan; 54(2):178-80. PubMed ID: 9117806
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Stability of an extemporaneous oral liquid aprepitant formulation.
    Dupuis LL; Lingertat-Walsh K; Walker SE
    Support Care Cancer; 2009 Jun; 17(6):701-6. PubMed ID: 19043742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.